Metaplastic Breast Carcinoma
NCI Definition: A group of invasive breast carcinomas characterized by the presence of an adenocarcinomatous component which is admixed with a dominant component that is composed of squamous cells, spindle cells, or mesenchymal cells. 
Metaplastic breast carcinomas most frequently harbor alterations in TP53, PIK3CA, MYC, RECQL4, and PTEN .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, PIK3CA Mutation, and PIK3CA H1047R are the most common alterations in metaplastic breast carcinoma .
There is 1 clinical trial for metaplastic breast carcinoma, of which 1 is open and 0 are completed or closed. Of the trial that contains metaplastic breast carcinoma as an inclusion criterion, 1 is phase 2 (1 open).
Nilotinib and paclitaxel are the most common interventions in metaplastic breast carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.